Page URL:

CRISPR technique refined to reduce errors

11 January 2016
Appeared in BioNews 834

Researchers have improved the genome-editing technique CRISPR/Cas9, reducing errors to nearly undetectable levels, according to a new study.

Improvements to the technique could pave the way for its use in patients with genetic diseases.

The CRISPR/Cas9 technique relies on a bacterial protein (Cas9) that is associated with a short piece of RNA. When Cas9 encounters a DNA sequence that matches up with that of its RNA guide, it cuts the DNA molecule at that location.

While the technique is very accurate, it is not infallible, and occasionally causes 'off-target effects' – cuts to the genome at sites where the DNA sequence is very close to the target sequence.

In the study, which was published in Nature, the scientists made changes to parts of the Cas9 which contact DNA molecules, creating a variant called SpCas9-HF1. While this version of the protein did not bind so effectively to DNA, it cut the genomes of lab-grown human cells in the correct places nearly as efficiently as the standard version of Cas9.

It also made far fewer 'off-target' mistakes: with no mistakes made with six out of seven test sequences, and only one made with the seventh. With the same guide sequences, the standard version of Cas9 made between 2 and 25 errors.

'We expected it would be improved in its specificity,' said Dr J. Keith Joung of Massachusetts General Hospital in Boston, lead author of the study, to GenomeWeb. 'What was striking was just how good it was. In many cases, all of the off-target effects caused by wild-type Cas9 drop to undetectable levels.'

Similar improvements to the accuracy of the CRISPR/Cas9 technique have recently been made by researchers at the Broad Institute (see BioNews 831). In that study, published in Science, changes were made to a different part of the Cas9 protein.

These improvements in accuracy are a step closer towards clinical applications of CRISPR. Unwanted damage to the genome could cause cell death or uncontrolled cell division and cancer, and this represents an important challenge.

Dr Joung is hopeful that the improved technique will be taken up straight away. 'We envision that our high-fidelity variant will supplant the use of standard Cas9 for many research and therapeutic applications,' he said.

However, the end point of these advances is not yet clear. Dr Charles Gersbach of Duke University in Durham, North Carolina, who was not involved in the research, told Nature News: 'At some point everyone needs to decide how specific is specific enough.'

5 March 2018 - by Kathryn Ashe 
Scientists have altered the Cas9 enzyme, increasing the number of sites that can be targeted by the CRISPR/Cas9 approach to genome-editing...
10 July 2017 - by Rikita Patel 
Researchers have revealed the structure and action of a new type of 'molecular scissors' known as Cpf1, which may improve CRISPR genome editing.
19 June 2017 - by Charlotte Spicer 
Two major biotech companies have criticised a recent study that claimed CRISPR may cause hundreds of unwanted mutations...
5 June 2017 - by Charlotte Spicer 
CRISPR may introduce hundreds of unwanted mutations into the genome, a small study finds...
25 April 2016 - by Dr Özge Özkaya 
Scientists have fine tuned the genome-editing tool CRISPR so that it can now edit a single 'letter' of DNA...
7 December 2015 - by Rhys Baker 
This 50-minute radio broadcast provides an 'appetiser' on CRISPR and the ethics surrounding genome editing...
7 December 2015 - by Dr Jane Currie 
An international summit has agreed conditions under which human genome editing, using techniques like CRISPR, should proceed...
30 November 2015 - by Ayala Ochert 
Using 'gene drive' technology, scientists have created mosquitoes with malaria-resistant genes that could spread rapidly into wild mosquito populations, potentially wiping out the disease in some areas...
30 November 2015 - by Dr Silvia Camporesi and Dr Lara Marks 
It is important to engage the public in the debate about genome editing as early as possible, and in a way that is as open as possible, to make sure that all possible voices are included...
16 November 2015 - by Ari Haque 
A US biotechnology start-up co-founded by two pioneers of CRISPR technology intends to begin gene editing in humans as part of an experimental treatment to target a rare genetic eye disorder...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.